Costello Caitlin
Moores Cancer Center, University of California, San Diego, 3855 Health Sciences Drive #0960, La Jolla, CA 92093, USA.
Ther Adv Hematol. 2017 Jan;8(1):28-37. doi: 10.1177/2040620716677523. Epub 2016 Nov 24.
Monoclonal antibodies (mAbs) have emerged as a promising new drug class for the treatment of multiple myeloma (MM). Daratumumab (DARA), a CD38 mAb, has demonstrated safety, tolerability and activity in a range of clinical trials, both as monotherapy and in combination strategies for MM. The favorable efficacy results in heavily pretreated patients with advanced MM have provided the rationale for the investigation of DARA in a number of ongoing and future phase II and III trials. The general tolerability of mAbs has allowed for widespread investigation and use of DARA among a variety of MM patients, however their use requires special consideration. Infusion-related reactions (IRRs), interference with blood compatibility assays and response assessments are all unique factors related to the use of DARA. This review provides an update of the results from the DARA clinical trials conducted to date, its future plans for investigation, and practical management considerations for the use of DARA in daily practice.
单克隆抗体（mAbs）已成为治疗多发性骨髓瘤（MM）的一种有前景的新型药物类别。达雷妥尤单抗（DARA）是一种CD38单克隆抗体，在一系列临床试验中已证明其安全性、耐受性和活性，无论是作为单药治疗还是用于MM的联合治疗策略。在晚期MM的重度预处理患者中取得的良好疗效结果为在多项正在进行的以及未来的II期和III期试验中研究DARA提供了理论依据。单克隆抗体的总体耐受性使得DARA能够在多种MM患者中得到广泛研究和使用，然而其使用需要特别考虑。输液相关反应（IRRs）、对血液相容性检测和疗效评估的干扰都是与使用DARA相关的独特因素。本综述提供了迄今为止进行的DARA临床试验结果的最新情况、其未来的研究计划以及在日常实践中使用DARA的实际管理考量。
